True that BIEL is a penny stock, and with a 25 billion AS, 75 billion shares needed to satisfy outstanding convertible notes, and a self-appointed CEO/President/Treasurer/CFO/Board Member that is in a position to own 100% of all company assets, it will likely stay a penny stock.
However, BioElectronics has patented and proven technology in the global multibillion-dollar pain space.
IMO, what is needed to move BIEL above penny status?
1. Profitable Sales
2. Share structure: once the income statement is healthy, the board needs to initiate a reverse split
3. The excessive investor risk needs to be lowered; the liabilities on the balance sheet created through self-dealing need to be unwound
4. Ongoing product development
5. Brand awareness
There is ample evidence that BIEL is a different company than it was under AW. The proof that it is a healthier company is when BIEL posts significant and increasing revenues together with positive cash-flow generated from profits not new loans.